Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 14/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441117 | 0.90 | DGAT1 (0.59) | DGAT1TSHR | |
| SCHEMBL440589 | 0.84 | DGAT1 (0.54) | DGAT1 | |
| Hydrochloric Acid SCHEMBL4930036 | 0.83 | DGAT1 (0.61) | DGAT1MEN1KMT2A | |
| SCHEMBL441196 | 0.82 | DGAT1 (0.54) | DGAT1ALDH1A1 | |
| SCHEMBL439191 | 0.82 | DGAT1 (0.57) | DGAT1 | |
| SCHEMBL440435 | 0.82 | DGAT1 (0.61) | DGAT1 | |
| SCHEMBL441603 | 0.82 | DGAT1 (0.53) | DGAT1 | |
| SCHEMBL407187 | 0.82 | DGAT1 (0.55) | DGAT1TSHRKMT2AALDH1A1 | |
| SCHEMBL440048 | 0.81 | DGAT1 (0.60) | DGAT1 | |
| SCHEMBL440737 | 0.81 | DGAT1 (0.52) | DGAT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | DGAT1 2/4885HTT 567/4885MEN1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.